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Abstract
Introduction: The aim of this study was to evaluate quantitative changes in OPG and RANKL proteins after treatment with strontium 
ranelate (SR) and ibandronate in patients with postmenopausal osteoporosis.
Material and methods: A total of 89 women with postmenopausal osteoporosis (PO), aged 51-85 years, patients of the Outpatient Clinic 
of Osteoporosis of the Military Teaching Hospital in Lodz, were enrolled in the study. The patients were randomly assigned to different 
therapies: ibandronate and (SR). Patients of the control group received only calcium and vitamin D3 supplements. The patients’ visits were 
repeated after three and six months. Measurements of b-CTX (C-terminal Telopeptide of type 1 collagen), osteocalcin, RANKL, osteoprote-
gerin (OPG), alkaline phosphatase concentrations in serum, as well as of total 24-hour calcium and phosphate levels in serum and urine, 
were carried out in material collected at baseline and after three and six months of therapy. Left hip and lumbar spine densitometry was 
done twice (at baseline visit and after six months).
Results: In all three groups there were no significant differences noted in the concentrations of OPG and RANKL serum protein levels 
during the study period. Both negative and positive correlations or tendencies of correlations were found between OPG serum concen-
trations and BMD changes in the SR group.
Conclusions: Both ibandronate and SR do not seem to cause any significant changes in OPG and RANKL protein serum levels during 
the first six months of treatment. OPG may play a role in osteoclast activity suppression in the course of treatment with ibandronate in 
patients with PO. OPG may play an important role in the mechanism of SR therapy and may be viewed as a potentially valuable parameter 
for monitoring and predicting the course of treatment with SR in PO. (Endokrynol Pol 2016; 67 (2): 174–184)
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Streszczenie
Wstęp: Celem badania była ocena ilościowych zmian stężeń białek OPG i RANKL po leczeniu ranelinianem strontu (RS) i ibandronianem 
u pacjentek z osteoporozą pomenopauzalną. 
Materiał i metody: Do badania zakwalifikowano 89 kobiet z osteoporozą pomenopauzalną (OP), w wieku 51–85, będących pacjentkami 
Poradni Leczenia Osteoporozy Uniwersyteckiego Szpitala Klinicznego im. WAM w Łodzi. Pacjentki losowo przydzielono do dwóch grup 
terapeutycznych, otrzymujących RS i ibandronian. Pacjentki z grupy kontrolnej otrzymywały tylko wapń i witaminę D. Chore odbywały 
wizyty w ośrodku w chwili rozpoczęcia badania, po 3 i 6 miesiącach, w trakcie których oznaczano stężenia: b-CTX (C-terminalny telopeptyd 
kolagenu typu I), osteokalcyny, osteoprotegeryny, RANKL, fosfatazy alkalicznej w surowicy, a ponadto wapnia oraz fosforanów zarówno 
w surowicy, jak i w moczu całodobowym. Badanie densytometryczne biodra i odcinka lędźwiowego kręgosłupa przeprowadzano przed 
włączeniem terapii oraz po 6 miesiącach leczenia.
Wyniki: W żadnej z grup nie stwierdzono istotnych statystycznie zmian stężeń OPG i RANKL w surowicy. Jednakże w grupie leczonej 
SR, zaobserwowano liczne dodatnie i ujemne korelacje oraz trendy statystyczne, pomiędzy stężeniami OPG a zmianami BMD. 
Wnioski: Zarówno ibandronian, jak i SR wydają się nie powodować istotnych zmian stężeń OPG i RANKL w surowicy, w trakcie pierwszych 
6 miesięcy terapii. W hamowaniu aktywności osteoklastów OPG może odgrywać istotną rolę, w trakcie terapii ibandronianem u pacjentek 
z OP. Może też pełnić ważną funkcję w mechanizmie działania RS i w związku z tym, może być rozpatrywana jako wartościowy parameter 
w monitorowaniu i przewidywaniu efektów leczenia RS w OP. (Endokrynol Pol 2016; 67 (2): 174–184)
Słowa kluczowe: osteoporoza; osteoprotegeryna; RANKL; ibandronian, ranelinian strontu 
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Introduction
In 1997, three independent research groups identified 
osteoprotegerin (OPG) [1–3]. OPG is a protein that be-
longs to the Tumour Necrosis Factor Receptor (TNFR) 
family and is produced by osteoblasts, as well as by 
other cell types, including peripheral blood lympho-
cytes [4–6]. OPG acts as a soluble decoy for the Receptor 
Activator for Nuclear Factor k B Ligand (RANKL) [3]. It 
has also been proven that OPG inhibits apoptosis via 
binding to the ligand associated with tumour necrosis 
factor (TNF) (TRAIL, TNF-Related Apoptosis-Inducing 
Ligand). RANKL is produced by many cell types, 
including osteoblasts, endothelial cells, and active T 
lymphocytes [3, 7]. RANKL is present in cell-bound and 
soluble forms (soluble RANKL, sRANKL). The recep-
tor for RANKL, called RANK (Receptor Activator  for 
Nuclear Factor k B), is present mainly on the surface of 
osteoclasts and dendritic cells. C-fms — the receptor for 
macrophage colony stimulating factor (M-CSF) — and 
RANK play an important role in osteogenesis [8]. Via 
binding to RANK in the presence of M-CSF, RANKL 
induces differentiation and activation processes in 
osteoclasts, prolongs their life, and strengthens their 
adhesion to bone surface [9, 10]. Many studies in recent 
years have confirmed the great importance of the OPG/ 
/RANK/RANKL system in the development of bone 
diseases [11]. Yano et al. [12] demonstrated that OPG 
serum concentration increases with age, but in women 
with postmenopausal osteoporosis it is higher in com-
parison with healthy controls. Furthermore, Kudlacek 
et al. [13] demonstrated that serum OPG concentrations 
significantly increase with age by an average of 2 pg/ 
/mL/year, both in women and men [13].
The relationship observed between Bone Turnover 
Markers (BTM) and the OPG/RANK/RANKL system 
has not yet been fully explored. In various studies, 
both positive and negative correlations were demon-
strated between the concentrations of OPG protein 
and RANKL [14, 15] vs. Bone Mineral Density (BMD). 
However, some authors question the occurrence of 
these relationships at all [13, 16, 17]. In men, a reverse 
relationship was observed between deoxypyridinoline 
(DPD), a resorption marker, and parathormone (PTH) 
activities and OPG concentrations [16]. In turn, in 
women of post-menopausal age, a negative correlation 
was demonstrated between serum markers of bone 
resorption/formation and OPG concentrations, while 
no such correlation was found for either OPG or resorp-
tion markers in urine and PTH concentrations [18]. In 
a study on male and female populations (the inhabitants 
of Iceland), a positive correlation was obtained between 
osteocalcin (OC), a bone formation marker, and OPG, 
while a reverse correlation between tartrate-resistant 
acid phosphatase (TRAP) and OPG was demonstrated 
only in the subpopulation of women [19]. Similar 
conclusions may be drawn from a study carried out 
by the Fahrleitner-Pammer team [17], which provides 
firm lines of evidence for the correlation between high 
concentrations of OPG and high BT levels, but in post-
menopausal women only [17]. The above-mentioned 
data are suggestive of a certain compensation mecha-
nism: an increase in OPG concentration is a response 
to intensified activity of osteoclasts and enhanced bone 
resorption. 
Ibandronic acid belongs to the group of amino-
bisphosphonates and represents the third and latest 
generation of bisphosphonates. The effectiveness and 
safety of ibandronate were proved in two important 
clinical trials: MOBILE and BONE [20, 21].
SR is used to treat postmenopausal osteoporosis 
in women and osteoporosis in men, exerting a double 
beneficial effect via several complex mechanisms on 
both osteoblasts and osteoclasts [22]. A number of clini-
cal trials were performed to evaluate the efficacy of SR 
in the therapy of osteoporosis [23, 24].
 The aim of the study was to determine whether 
OPG and RANKL are reliable indicators of effective 
postmenopausal osteoporosis treatment with SR and 
ibandronate.
Material and methods
Material
A total of 89 women, aged 51–85 years, and with di-
agnosed osteoporosis after menopause were enrolled 
into the study. All the participants were patients of the 
Outpatient Clinic of Osteoporosis of the Military Teach-
ing Hospital in Lodz, Poland.
The patients were diagnosed with osteoporosis via 
hip and/or lumbar spine DXA (T-score ≤ –2.5 SD). All the 
enrolled women had had the last menstrual bleeding at 
least 12 months before the study onset. The exclusion 
criteria included:
 — chronic administration of bone metabolism affect-
ing agents: bisphosphonates, SR, sodium fluoride, 
denosumab, oestrogens or hormonal replacement 
therapy, selective oestrogen receptor modulators, 
glucocorticosteroids, anti-epileptic drugs, aromatase 
inhibitors, GnRH analogues, and chemotherapy;
 — endocrine disorders significantly affecting bone 
resorption processes, such as: hyperparathyroidism, 
active hyperthyroidism, hyperprolactinaemia, and 
hypogonadism;
 — chronic renal failure (glomerular filtration rate 
< 35 mL/min [25]);
 — malabsorption;
 — diagnosed cancer, malignant tumour, or process;
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 — chronic systemic disease that could have signifi-
cantly affected bone metabolism;
 — no written consent to participate in the study.
All the participants received supplementation of 
calcium (calcium carbonate, gluconate, or citrate) at 
a dose that ensured adequate intake of 1500 mg elemen-
tal calcium. In addition, all the patients received 400–800 
IU of native vitamin D3 per day in a formulation, either 
containing calcium salt or as a separate supplement. 
Following the obligatory recommendations, the dose 
was gradually increased throughout the study period 
up to 800–1000 IU per day. Calcium and vitamin D3 sup-
plements were purchased by the patients themselves. 
In order to determine calcium deficiency, the patients 
were questioned at the beginning of the study about 
their dietary habits. Twenty-nine patients, who com-
pleted the study, received oral ibandronate sodium in 
150 mg (Bonviva, Roche) doses, every 30 days for six 
months. Twenty-four remaining study participants 
received orally 2.0 grams of SR (Protelos, Servier) once 
a day. Both study drugs were provided free of charge 
by their manufacturers. The women from the control 
group (15 patients) received only calcium and vitamin 
D3 supplementation. At study onset, the examined 
groups did not differ significantly in terms of age or 
BMD. The compliance and adherence to the therapy 
were assessed on the basis of patient declarations and 
returned empty drug packaging units. In cases of 
non-compliance to visit schedules, the patients were 
contacted by phone. 
The patients, qualified to the study, paid visits 
every three months in order to replenish medication 
stocks, for evaluation of compliance to prescribed drug 
administration, and for planned examinations. Blood 
samples were collected from fasting patients at the 
inclusion visit and after three and six months to assay 
b-CTX, OC, sRANKL, OPG, total calcium, phosphates, 
and alkaline phosphatase. 
In addition, all the patients provided a representa-
tive urine sample from 24-hour collection to determine 
24-hour urine calcium and phosphate excretion rates. 
Hip and lumbar spine DXA were performed twice 
(at enrolment and after six months) in all the patients. 
All the enrolled patients remained under care of the 
Outpatient Clinic of Osteoporosis, Military Teaching 
Hospital in Lodz throughout the whole study period. 
Methods
Densitometry
Hip (Neck, Trochanter, Total Hip regions ) and lumbar 
spine ( L2–L4 region) BMD was evaluated by dual-
energy X-ray absorptiometry (DXA) on a Norland XR46 
machine (Norland Corp., Fort Atkinson, WI, USA) 
at baseline and after six months of the therapy. The 
minimum acceptable precision for technologists in our 
facility does not exceed the values: 1.9% (LSC = 5.3%) 
for Lumbar Spine, 1.8% (LSC = 5.0%) for Total Hip, and 
2.5% (LSC = 6.9%) for Femoral Neck. 
Laboratory tests and OPG, RANKL, and bone 
marker concentration assessments
Biochemical assays, including serum concentrations of 
bone turnover markers, OPG, and sRANKL proteins, 
were carried out by means of the following methods 
and sets:
 — the serum alkaline phosphatase concentrations as 
well as total serum calcium and phosphate levels 
and 24-hour urine excretion rates were assessed 
using a colorimetric method with an Olympus 
analyser (Olympus Life and Material Sciences, 
O’Callaghan’s Mills, Ireland) and Beckman Coulter 
(Brea, California) kits, according to the manufac-
turer’s instructions;
 — the serum osteocalcin (OC) and b-CrossLaps 
(C-terminal telopeptide of type 1 collagen, b-CTX) 
concentrations were evaluated by the electro-
chemiluminescence method with an Elecsys 2010 
analyzer (Roche Diagnostics, Penzberg, Germany) 
and Roche Diagnostics kits in compliance with the 
manufacturer’s recommendations. Reference values 
for OC were 0.5 to 300 ng/mL and for b-CTX 0.01 
to 6.0 ng/mL;
 — OPG and sRANKL by the ELISA (Enzyme-Linked 
Immunosorbent Assay) method, using kits from Bio-
medica Gruppe (Vienna, Austria) and a Metertech 
e960 spectrophotometer (Metertech Inc., Taiwan). 
The assays were carried out at wave length of 450 
nm, following the manufacturer’s instructions. Nor-
mal median sRANKL and OPG values for women 
were, respectively, 0.37 and 1.8 pomol/L.
The serum used to assay OPG, sRANKL, b-CTX, 
and OC concentrations was frozen immediately after 
centrifugation of collected blood and stored at –70°C 
until use. The other laboratory tests, i.e. calcium and 
phosphate levels in serum and 24-hour urine, as well 
as alkaline phosphatase concentrations, were measured 
immediately after sampling. 
Statistical analysis
Statistical analysis covered the results of calcium-
phosphate metabolism, serum RANKL and OPG 
concentrations, bone markers, and BMD
The study data are presented as means ± 0.95 confi-
dence intervals. For all statistical analyses, the level 
of significance (p value) was determined at 0.05. The 
analysis of variance and the multivariate analysis of 
variance (ANOVA/MANOVA) were used, together with 
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repeated measurements to verify if BMD, OPG, RANK, 
and RANKL gene expression, alkaline phosphatase, 
calcium, and phosphate levels in serum and calcium, 
and phosphate urinary excretion rates changed after the 
applied treatment over the time period of the trial. Data 
distribution normality was checked in each group, using 
the Shapiro-Wilk’s test. The homogeneity of variance 
was evaluated, using Hartley’s F-max, Cochran’s C, and 
Bartlett’s chi-square tests. Mauchly’s sphericity test was 
used to verify whether the criteria required for the use 
of variance analysis with repeated measurements were 
met. Multiple post-hoc comparisons were performed 
by Scheffe’s test.
Correlation analysis
Spearman’s rank correlation coefficient test was em-
ployed to evaluate the correlation between assessed 
parameters.
Results
Sixty-eight patients at the age of 51–85 years completed 
the study. The baseline characteristics of the study 
groups are presented in Table I. The patients on SR 
were those who most often discontinued the treatment 
(31.4%). A slightly lower percentage of women in the 
control group (25%) and only 14.7% of patients on 
ibandronate left the therapy before study completion; 
see Table II for withdrawal reasons.
Comparative analyses of parameters in and 
among study groups
Analysis of BMD
A non-significant (1.2%) increase of BMD in the femoral 
neck was observed after six months of therapy, both in 
the control group (1.2%) and in the SR group (1.6%). 
Regarding other regions, a slight BMD increase was 
Table I. Baseline characteristics of studied patient groups
Tabela I. Podstawowa charakterystyka grup pacjentów uczestniczących w badaniu
Strontium renelete Ibandronate Control group
Age (years ± SD) 66.8 ± 7.4 68.1 ± 8.1 69.2 ± 8.1
BMI [kg/m2] 24.8±3.8 26.8 ± 4.1 26.2 ± 2.9
Vertebral fractures (number/%] 3/12.5 8/28.6 1/6.7
Forearm fractures (number/%) 9/37.5 14/48.3 2/13.3
Hip fractures (number/%) 0/0 1/3.5 1/6.7
T-score ± SD/Neck BMD [g/cm2 ± SD] –3.10 ± 0.45/ 
/0.6246 ± 0.0523
–3.20 ± 0.55/ 
/0.6126 ± 0.0641
–3.21 ± 0.58/ 
/0.6109 ± 0.0677
T-score ± SD/Trochanter BMD [g/cm2 ± SD] –2.96 ± 0.66/ 
/0.4606 ± 0.0718
–2.88 ± 0.67/ 
/0.4714 ± 0.0767
–2.92 ± 0.34/ 
/0.4688 ± 0.0365
T-score ± SD/TH BMD [g/cm2 ± SD] –2.37 ± 0.59/ 
/0.6637 ± 0.072
–2.31 ± 0.63/ 
/0.6722 ± 0.0776
–2.35 ± 0.48/ 
/0.6671 ± 0.0589
T-score ± SD/L2–L4 BMD [g/cm2 ± SD] –2.35 ± 0.91/ 
/0.7230 ± 0.1457
–2.44 ± 0.59/ 
/0.7066 ± 0.0955
–2.37 ± 0.71/ 
/0.7175 ± 0.1145
Calcium concentration in serum [mmol/L] 2.53 ± 0.09 2.53 ± 0.08 2.54 ± 0.06
Phosphate concentration in serum [mmol/L] 1.2 ± 0.19 1.17 ± 0.17 1.16 ± 0.18
24-hour calcium urine excretion [mmol/24 h] 3.65 ± 2.35 4.73 ± 2.6 4.41 ± 3.13
24-hour phosphate urine excretion [mmol/24 h] 24.7 ± 13.05 20.54 ± 9.28 23.29 ± 9.82
Alkaline phosphatase concentration in serum [IU/L] 82.54 ± 20.79 88.72 ± 28.88 79.73 ± 14.94
Table II. Reasons for patient discontinuation
Tabela II. Przyczyny przerwania terapii przez pacjentki
The percent of patients,  
who withdrew per group
Withdrawal reasons
Side effects Loss of interest in study  
and personal reasons
Loss of contact
Strontium ranelate 31.40% 100% 0% 0%
Ibandronate 14.70% 60% 0% 40%
Control group 25% 0% 80% 20%
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also observed: 2.9% and 3.1% in the femur trochanter, 
2.9% and 1.1% in Total Hip (TH), and 2.5% and 2.0% in 
the lumbar spine for the SR and ibandronate groups, 
respectively. The BMD differences were not statisti-
cally significant over time or between groups (data 
not shown).
Analysis of serum RANKL, OPG, OC and b-CTX 
concentrations 
Serum sRANKL concentrations above detection limits 
were observed in a small number of the patients only: 
three in the control group, eleven on ibandronate and 
seven on SR.
Very low serum concentrations of sRANKL protein 
were seen throughout the entire study period in all 
the study groups (median value < 0.001 pmol/L vs. 
normal median value of 0.37 pmol/L, specified by the 
manufacturer). The results were insignificant among 
and within the groups (Fig. 1).
The differences in OPG concentrations did not 
reveal any significant changes under the applied treat-
ment, nor were any significant differences observed 
among the groups (Fig. 2).
OC concentrations decreased by as much as 43% 
(p < 0.001) from baseline in the group on ibandronate 
(Fig. 3). Moreover, OC levels after six months on iban-
dronate therapy were significantly lower (p = 0.049) 
than in the control group; OC differences in the other 
groups did not attain significance. 
b-CTX concentrations (Fig. 4) demonstrated sig-
nificant falls of the marker levels in the group on 
ibandronate, namely by 55% and 73% after three and 
six months, respectively (p < 0.001). Moreover, b-CTX 
values after six months of ibandronate therapy were 
significantly lower than those in the control group 
(p < 0.01). In the course of the therapy with SR, 
the concentrations of the marker presented with 
a slight insignificant reduction by 28% after six 
months of therapy, but it was not statistically signifi-
cant (p = 0.41). 
Correlations among studied parameters (Table III)
Correlations between BMD and the other parameters 
(Table IV)
Correlations between femoral neck BMD and serum 
concentrations of bone markers, RANKL, and OPG 
proteins 
We observed positive correlations between changes in 
femoral neck BMD values and OC (R = 0.388; p < 0.05) 
and b-CTX (R = 0.407; p < 0.05) concentrations in serum 
in the ibandronate-treated group.
In the SR group an insignificant positive correla-
tion (R = 0.375; p = 0.07) between OPG concentration 
differences and changes in the femoral neck BMD 
was found.
 In the other groups, no significant correlations were 
observed between changes of the above-mentioned 
parameters and femoral neck BMD or between femoral 
neck BMD increase/decrease and changes in the con-
centration of RANKL protein in serum. 
Figure 1. Treatment-induced RANKL concentration changes in 
serum
Rycina 1. Zmiany stężeń RANKL w wyniku zastosowanej terapii
Figure 2. Treatment-induced OPG concentration changes in 
serum
Rycina 2. Zmiany stężeń OPG w wyniku zastosowanej terapii
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Correlations between femoral trochanter BMD 
changes and serum concentrations of bone markers, 
OPG, and RANKL
There was a significant, negative correlation (R = –0.567; 
p < 0.01) between femoral trochanter BMD changes 
and the differences in OC concentration in the group on 
SR. In the other groups, no significant correlations were 
found between increase/decrease of the above-mentioned 
parameter and femoral trochanter BMD differences or 
between femoral trochanter BMD changes and serum 
concentrations of OPG, RANKL, or b-CTX marker.
Correlations between TH BMD and serum  
concentrations of bone markers, OPG,  
and RANKL
A significant correlation was observed between 
increased OPG concentrations and BMD in the SR 
group (R = 0.508; p < 0.05). No significant relation-
ship was found in the other groups between increase/ 
/decrease of the above-mentioned parameter and TH 
BMD differences or between TH BMD values and 
serum concentrations of RANKL protein, b-CTX, and 
OC markers.
Figure 3. Treatment-induced osteocalcin concentration changes 
in serum
Rycina 3. Zmiany stężeń osteokalcyny w wyniku zastosowanej 
terapii
Figure 4. Treatment-induced b-CTX concentration changes in 
serum
Rycina 4. Zmiany stężeń b-CTX w wyniku zastosowanej terapii
Table III. Correlations between changes of studied parameters
Tabela III. Korelacje pomiędzy zmianami badanych parametrów
Correlation 
between
OPG RANKL b-CTX OC
Group R value P value Group R value P value Group R value P value Group R value P value
Neck BMD SR 0.375 0.07 All NS NS IBA 0.407 < 0.05 IBA 0.388 < 0.05
Trochanter BMD All NS NS All NS NS All NS NS SR –0.567 < 0.01
Total Hip BMD SR 0.508 < 0.05 All NS NS All NS NS All NS NS
L2–L4 BMD Control 0.648 < 0.01 All NS NS All NS NS All NS NS
OC All NS NS All NS NS IBA 0.793 < 0.001 N/A N/A N/A
OC All NS NS All NS NS SR 0.824 < 0.001 N/A N/A N/A
OC All NS NS All NS NS Control 0.713 < 0.01 N/A N/A N/A
b-CTX All NS NS All NS NS N/A N/A N/A IBA 0.793 < 0.001
b-CTX All NS NS All NS NS N/A N/A N/A SR 0.824 < 0.001
b-CTX All NS NS All NS NS N/A N/A N/A Control 0.713 < 0.01
OPG N/A N/A N/A All NS NS All NS NS NS NS NS
RANKL All NS NS N/A N/A N/A All NS NS NS NS NS
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Correlations between lumbar spine BMD and serum 
concentrations of bone markers, OPG, and RANKL
A significant correlation was found (R = 0.648; p < 0.01) 
between increased lumbar spine BMD and serum 
OPG concentrations in the control group. Regarding 
other groups, no significant correlations were observed 
between increase/decrease of the above-mentioned pa-
rameter and lumbar spine BMD differences or between 
BMD values in that region and serum concentrations of 
RANKL protein and b-CTX and OC markers.
Correlations among the differences in serum 
RANKL, OPG, OC, and b-CTX concentrations
We observed positive correlations between OC and 
b-CTX concentration changes in all groups, i.e. in the 
ibandronate-treated group (R = 0.793; p < 0.001), the 
SR-treated group (R = 0.824; p < 0.001), and in the 
control group (R = 0.713; p < 0.01). No significant 
changes were observed between differences of the 
above-mentioned markers and RANKL and OPG, as 
well as between OPG and RANKL.
Correlations between BMD changes and the initial 
serum concentrations of OPG and RANKL proteins 
and OC and b-CTX bone markers
There were significant, negative correlations be-
tween the initial concentrations of OC (R = –0.442; 
p < 0.05) and b-CTX (R = –0.407; p < 0.05) in serum and 
femoral neck BMD changes in the ibandronate-treated 
group, as well as a significant correlation between OPG 
values and femoral neck BMD changes in the control 
group (R = 0.723; p < 0.01) (data not shown). Regarding 
other groups, no significant correlations were found 
between values of the above-mentioned parameters 
and femoral neck BMD differences or between BMD 
changes in the femoral neck and serum RANKL protein 
concentrations. 
We observed a significant negative correlation 
(R = –0.391; p < 0.05) between TH BMD changes and 
OC levels in the ibandronate-treated group. Moreover, 
in the patients on SR, there was a negative correlation 
(R = –0.408; p < 0.05) between TH BMD differences and 
serum OPG concentrations. No significant correlation 
was found between the values of the above-mentioned 
parameters and TH BMD differences in the other 
groups nor between BMD changes in that region and 
b-CTX or RANKL concentrations. 
A significant, negative correlation (R = –0.534; 
p < 0.01) was demonstrated in the group, treated with 
SR, between lumbar spine BMD changes and OPG 
concentrations in serum. No significant correlations 
were found in the other groups between the values 
of the above-mentioned parameter and lumbar spine 
BMD differences nor between BMD changes in that 
region and serum concentrations of RANKL protein, 
OC and b-CTX.
The observed relationships between femoral tro-
chanter BMD differences and initial serum concentra-
tions of bone markers and OPG or RANKL proteins 
were statistically insignificant. 
Discussion
In the presented study, the observed differences in 
serum OPG and sRANKL concentrations were statisti-
cally insignificant. Moreover, the measurable values of 
sRANKL were obtained in a small number of the pa-
tients. Additionally, a significant decrease in serum OC 
concentrations was noted after six months, as well as of 
b-CTX and ALP after three and six months of therapy. 
After six months of therapy with ibandronate the values 
of the former two bone markers were significantly lower 
than in the control group. 
Moreover, we found positive correlations between 
femoral neck BMD changes and OC and b-CTX con-
centrations in serum. The obtained results demonstrate 
favourable therapeutic effects of ibandronate. 
The data, indicating a significant impact of bispho-
sphonates on RANKL and OPG secretion rates, have, 
in their majority, been obtained from in vitro studies 
[26, 27].
Reports that raise the issue of the effects of bis-
phosphonates, especially of ibandronate, on the OPG/ 
/RANK/RANKL system in in vivo studies with par-
Table IV. Correlations between BMD changes and initial serum concentrations of OPG, RANKL, b-CTX, and OC
Tabela IV. Korelacje pomiędzy zmianami BMD a początkowymi stężeniami: OPG, RANKL, b-CTX i OC
Correlation 
between
OPG RANKL b-CTX OC
Group R value P value Group R value P value Group R value P value Group R value P value
Neck BMD Control 0.723 < 0.01 All NS NS IBA –0.407 < 0.05 IBA –0.442 < 0.05
Trochanter BMD All NS NS All NS NS All NS NS All NS NS
Total Hip SR –0.408 < 0.05 All NS NS All NS NS IBA –0.391 < 0.05
L2–L4 BMD SR –0.534 < 0.01 All NS NS All NS NS All NS NS
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ticipation of osteoporotic patients, are rather scarce in 
number, with equivocal conclusions. 
Dobnig et al. [28] beside a significant improvement 
of BMD in the femoral neck and trochanter in patients 
with postmenopausal osteoporosis, submitted to 
a year long therapy with alendronate and risendronate, 
demonstrated a significant drop of CTX and OC con-
centrations — similar to our results — after just two 
months of therapy, which was maintained throughout 
the entire period of their study. Unlike in our results, 
OPG concentration significantly increased after six 
months of therapy, and that tendency remained for 
the subsequent six months, while the obtained values 
were significantly higher at all time points vs. the control 
group. Regarding sRANKL, as in our study, they did 
not demonstrate any significant differences, either in 
time or among the groups. Moreover, the occurrence 
of significantly positive correlations between OPG and 
CTX concentration changes after two months (r = 0.49; 
p = 0.001) was demonstrated, OPG and BMD of the 
femoral neck and trochanter after six and 12 months 
of therapy with bisphosphonates [28], which we did 
not see in our study. 
Reyes-Garcia et al. [29], while having administered 
alendronate for 12 months to patients with osteopo-
rosis after menopause, obtained a significant decrease 
of OPG concentration after 12 months of treatment, 
while the RANKL concentration increased at all the 
studied time points, i.e. after three, six, and 12 months 
from the therapy onset. Similarly as in our experiment, 
the concentrations of the bone fraction alkaline phos-
phatase and CTX demonstrated an expected fall under 
the therapy. However, the researchers also failed to 
demonstrate any correlations between the concentra-
tions of OPG, sRANKL, and bone turnover markers, 
at the beginning and in the course of the study. They 
only found a correlation between CTX concentration 
changes (r = –0.304; p < 0.05) and BMD increase after 
12 months [29]. 
Studying the effects of the risedronate on OPG con-
centration in serum, Karadag-Saygi et al. [30] obtained 
a significant fall in concentration of the above-mentioned 
compound in serum after one, three, and six months 
of therapy; however, the same effect was observed in 
the control group, which had been receiving the sup-
plements of calcium and vitamin D3 only. Moreover, 
analogously to our results, the authors of the study 
found a significant decrease in the concentrations of 
CTX and OC markers after three and six months of the 
therapy with risedronate, respectively [30]. 
Different results were obtained by the research group 
of Dundar et al. [31], who observed increased OPG and 
decreased RANKL concentrations in serum after three 
and six months of treatment with risedronate [31].
Anastasilakis et al. [32], despite a significant fall of 
RANKL concentration in serum of all studied groups, 
including the control, did not demonstrate any signifi-
cant differences in RANKL or OPG concentrations dur-
ing the period of six months among patients receiving 
risendronate in a dose of 35 mg/week, or proanabolic 
teriparatide (subcutaneously) [32]. 
In another study, after 15 months of therapy with 
alendronate a significant increase in BMD values was 
observed for the lumbar spine, with an insignificant 
increase of BMD for the femoral neck. After three 
months of mixed therapy, and in contrast to our results, 
the serum concentrations of OPG and RANKL demon-
strated significant falls. The same was true with regards 
to CTX, but this time it was the same as in our study. All 
of the falls in the above-mentioned concentrations were 
maintained until the end of observation [33]. 
However, Choi et al. [34], having administered small 
(20 mg per week) doses of alendronate for 12 weeks 
to female patients with low bone mass, despite the 
obtained values of bone markers (OC, CTX), similar to 
our results, failed to obtain any changes in serum OPG 
concentration after the therapy [34]. 
Analysing the effects of antiresorptive medications, 
it is also worth mentioning the results of the study 
by Bashir et al. [35], who evaluated the influence of 
12-month hormonal replacement therapy (HRT) with 
administration of raloxifene to female patients with 
postmenopausal osteoporosis. They demonstrated 
a significant drop of expression of all the three elements 
of the OPG/RANK/RANKL system, after just six months 
of using both therapy forms and a significant decrease 
of OPG concentration in serum after just one month 
of treatment, and that tendency was maintained until 
the end of the study. 
However, similarly as in our results, the authors of 
the study obtained positive values of sRANKL only in 
a small group of patients; in all the other cases sRANKL 
values were below assayable level [35]. 
In our experiment, neither in any of the three groups 
nor among the groups were any significant differ-
ences observed in serum concentrations of OPG and 
RANKL protein. The changes of serum OC and b-CTX 
concentrations in the patients treated with SR were in-
significant. A detailed statistical analysis demonstrated 
a significant, positive correlation and a positive depend-
ence, although statistically insignificant (p = 0.07), 
between the differences in OPG concentrations and 
BMD changes, namely in TH and femoral neck in the 
group of patients on SR. Simultaneously, we demon-
strated a significantly negative correlation between 
BMD changes in the femoral trochanter and changes 
of OC concentration in serum. Analysing the predictive 
values of OPG and RANKL among the patients treated 
182
PR
A
C
E 
O
RY
G
IN
A
LN
E
Assesment of OPG, RANKL, bone tumour markers serum levels, and BMD  Michał Stuss et al.
with SR, we found significantly negative correlations 
between the initial OPG concentration and the differ-
ences in TH and lumbar spine BMD values, which may 
indicate a need to evaluate OPG and RANKL when 
qualifications to optimal treatment are defined and/or 
considered. 
The lack of expected, significant differences in the 
concentrations of bone markers, both of bone formation 
(OC) and bone resorption (b-CTX) markers in female 
patients receiving SR, may suggest a lack of therapeutic 
effectiveness of the above-mentioned drug in the evalu-
ated group. Taking into account the reasonably well 
documented effects of SR on concentration changes of 
the following bone markers: bone fractions of ALP, CTX, 
N-terminal telopeptide of collagen type I, propeptides 
of collagen type I in randomised, double-blinded clini-
cal studies [23, 24, 36], any other possible explanation 
for the observed lack of changes in BT marker values 
should in fact be sought in the poor compliance and 
persistence with prescribed therapy, despite declara-
tions of the patients trying to present the opposite 
picture. However, the opinions are divided regarding 
the variability of serum OC changes under the effect 
of SR treatment [36]. 
The studies that undertook the issue of SR effects 
on the OPG/RANK/RANKL system are very scarcely 
represented by literature reports and were almost 
exclusively conducted in in vitro conditions [37–40], 
where cells of the osteoblastic line were predominantly 
the object of analysis, while in vivo studies on rodents 
were much less frequent [40, 41]. The lack of any stud-
ies in humans is a considerable impediment to any 
unequivocal conclusions from our study, based on 
available literature reports. 
Peng et al. [41] evaluated the effects of an eight-
week therapy with strontium in mice with inactivated 
genes for OPG and failed to demonstrate a favourable 
anabolic response, represented by an increased number 
of osseous trabecullae and increased bone volume. Nor 
did they find any suppression of osteoclastogenesis 
nor inhibition of bone resorption process. The above-
mentioned effects were only observed in mice of wild-
type strain [41]. 
Only in January 2012 a report was published [42], in 
which its authors indicate the role of osteoprotegerin in 
the therapeutic effects of strontium in a clinical study. 
Assays were performed on 2335 enrolled participants 
of the TROPOS trial, in whom serum OPG concentra-
tions were determined at point zero and after 3, 6, 12, 
24, and 36 months of therapy with SR. In contrast to 
our results, that research demonstrated that from the 
third month of drug administration, OPG concentra-
tions were significantly higher than those in the control 
group and that the favourable effect was maintained 
until the end of the trial [42]. 
In our previous study [43] we showed that both 
ibandronate and SR seem not to exert any significant 
changes in gene expression levels of the OPG/RANK/ 
/RANKL system during the first six months of therapy. 
This study was the first attempt to evaluate the effects 
of ibandronate and one of the few to assess the influ-
ence of SR on serum OPG and RANKL concentration 
changes in female patients with postmenopausal 
osteoporosis. We are aware that our study has some 
limitations, i.e. only six-month observation period and 
rather small groups of patients. However, the available 
literature data, specifying the effects of either therapy 
on changes within the OPG/RANK/RANKL system, 
are also ambiguous and equivocal. It is suggestive of 
some additional, still concealed factors, which may 
significantly determine or control the activity of the 
above-mentioned system at transcription and/or trans-
lation levels [44–46].
There is currently no official position on the use 
of OPG and RANKL as bone metabolism markers in 
the diagnosis and treatment of osteoporosis [47–49]. 
The high diversity and heterogeneity of these mark-
ers’ concentrations in the serum may result from their 
involvement in a number of other bone and joints dis-
eases, as well as other systemic and metabolic disorders, 
including rheumatoid arthritis, ankylosing spondylitis, 
and hypertension [50–53].
Conclusions
1. According to our results, sRANKL and OPG do 
not seem to be reliable indicators of effective post-
menopausal osteoporosis treatment with SR and 
ibandronate.
2. Neither ibandronate nor SR seem to induce any 
significant changes in the production of OPG and/
or RANKL protein in serum during the first six 
months of therapy.
3. OPG may hold a significant function in the thera-
peutic mechanism of SR, and OPG concentration in 
serum may be considered as a potentially valuable 
parameter in monitoring and prognosing the further 
course of therapy with SR in postmenopausal osteo-
porosis. However, to state a clear conclusion further 
studies are needed on large groups of patients.
4. OPG may play a specific role in suppressing the 
activity of osteoclasts in the course of therapy with 
ibandronate administered to female patients with 
postmenopausal osteoporosis, but further studies 
are needed on large groups of patients.
5. Six-month therapy with SR and ibandronate ad-
ministered in female patients with postmenopausal 
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osteoporosis is too short for a reliable evaluation of 
achieved improvement of BMD. 
6. Bone turnover markers, especially bCTX, ALP, and 
OC, may be helpful in an evaluation of the therapeu-
tic efficacy of ibandronate administered to patients 
with postmenopausal osteoporosis.
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